Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer.
Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer.
复制标题
DOI：
10.1158/1055-9965.epi-16-0488
复制
发表时间：
2016-12
期刊：
影响因子：
--
通讯作者：
Smith SS
中科院分区：
文献类型：
--
作者：
Wittig K;Yamzon JL;Smith DD;Jeske DR;Smith SS
格里森评分(GS)的升级通常被认为是主动监测(AS)期间退出最终治疗的触发因素。预测一般事务人员升级的潜力将对评估是否符合资格具有价值。在这种情况下，我们评估了前列腺液(EPS)表达的手术前标本中生物标记物的表现。尽管EPS体积、回收的总RNA和RNA表达生物标记物(TMPRSS2：ERG、PCA3、PSA)在预测活检结果和预测符合主动监测条件的患者的升级方面都已成功，但它们无法预测符合NCCN指南的主动监测患者的升级。这些生物标志物并不能提高标准临床参数的适应症升级的预测能力。这一地区将需要更多的生物标志物。
Gleason Score (GS) upgrading is generally considered a trigger for exit to definitive treatment during active surveillance (AS). Predicting the potential for GS upgrading would be of value in assessing AS eligibility. We assessed the performance of biomarkers in pre-surgical specimens of expressed prostatic secretion (EPS) in this setting. Although EPS volume, total recovered RNA, and RNA expression biomarkers (TMPRSS2: ERG, PCA3, PSA) have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients, they were unable to predict upgrading in patients eligible for active surveillance under NCCN guidelines. These biomarkers do not improve the prediction of upgrading over indications from standard clinical parameters. Additional biomarkers will be needed in this area.